D. Spitz

发表

Phase II trial of weekly single-agent paclitaxel in platinum/paclitaxel-refractory ovarian cancer.

M. Baker, M. Markman, James O Hall, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A multicenter, open-label, expanded phase 2 study to evaluate the safety and efficacy of etirinotecan pegol, a polymer conjugate of irinotecan, in women with recurrent platinum-resistant or refractory ovarian cancer.

G. Rustin, I. Vergote, J. Bendell, 2017, Gynecologic oncology.

Phase II study of NKTR-102 in women with platinum-resistant/refractory ovarian cancer.

G. Rustin, I. Vergote, C. Pippitt, 2010 .

Unmasking of cryptic natural killer (NK) cell recognition sites on chronic lymphocytic leukemia lymphocytes

D. Spitz, D. Zucker‐Franklin, Z. Nabi, 1988, American journal of hematology.

Efficacy and safety of buparlisib, a PI3K inhibitor, in patients with malignancies harboring a PI3K pathway activation: a phase 2, open-label, single-arm study

F. Meric-Bernstam, S. Piha-Paul, F. Braiteh, 2019, Oncotarget.

Adavosertib with Chemotherapy in Patients with Primary Platinum-Resistant Ovarian, Fallopian Tube, or Peritoneal Cancer: An Open-Label, Four-Arm, Phase II Study

Suzanne F. Jones, A. Oza, J. Cragun, 2021, Clinical Cancer Research.

Phase II study of Vigil® DNA engineered immunotherapy as maintenance in advanced stage ovarian cancer.

N. Senzer, J. Nemunaitis, L. West, 2016, Gynecologic oncology.

Genomic mutation profiling (GMP) and clinical outcome of patients treated with buparlisib (PI3K inhibitor) in the “Signature” program.

S. Papish, S. Piha-Paul, B. Hellerstedt, 2015 .

Adavosertib with chemotherapy (CT) in patients (pts) with platinum-resistant ovarian cancer (PPROC): An open label, four-arm, phase II study.

Suzanne F. Jones, A. Oza, J. Cragun, 2019, Journal of Clinical Oncology.

Phase II study of Vigil ® DNA engineered immunotherapy asmaintenance in advanced stage ovarian cancer

N. Senzer, J. Nemunaitis, L. West, 2016 .

Randomized multicenter phase II trial comparing two schedules of etirinotecan pegol (NKTR-102) in women with recurrent platinum-resistant/refractory epithelial ovarian cancer.

G. Rustin, I. Vergote, L. Dirix, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long-term follow-up of efficacy and safety of selinexor maintenance treatment in patients with TP53wt advanced or recurrent endometrial cancer: A subgroup analysis of the ENGOT-EN5/GOG-3055/SIENDO study.

J. Pérez-Fidalgo, J. Buscema, D. Spitz, 2024, Gynecologic oncology.

The role of NKTR-102 in women with platinum resistant/refractory ovarian cancer and failure on pegylated liposomal doxorubicin (PLD).

G. Rustin, I. Vergote, L. Dirix, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.